Sign up to save your podcasts
Or
Share Poster Pearl: Elacestrant + Abemaciclib for ER+/HER2- Metastatic Breast Cancer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Poster Pearl: Elacestrant + Abemaciclib for ER+/HER2- Metastatic Breast Cancer
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Erika Hamilton, MD
The ELECTRA trial is seeking to evaluate the combination of elacestrant with abemaciclib in patients with ER+/HER2- metastatic breast cancer regardless of metastatic site and ESR1 status to see if this could be an all-oral treatment option before using fulvestrant-based combinations or chemotherapy-based regimens. And now, the preliminary results are here. Joining Dr. Charles Turck to share what we’ve learned so far from the ELECTRA trial is study investigator Dr. Erika Hamilton.
View all episodes
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Erika Hamilton, MD
The ELECTRA trial is seeking to evaluate the combination of elacestrant with abemaciclib in patients with ER+/HER2- metastatic breast cancer regardless of metastatic site and ESR1 status to see if this could be an all-oral treatment option before using fulvestrant-based combinations or chemotherapy-based regimens. And now, the preliminary results are here. Joining Dr. Charles Turck to share what we’ve learned so far from the ELECTRA trial is study investigator Dr. Erika Hamilton.